Table 1 Clinicopathological presentations of LCH patients

n (%)

148

60 (41%)

88

Gender, n (%)

0.689, ns

Male

88 (59%)

34 (39%)

54

Female

60 (41%)

26 (43%)

34

Onset age, n (y, %)

0.575, ns

Median (years, range)

2 (0–16)

2 (0–11.8)

2 (0–16)

< 1

43 (29%)

18

25

1 ~ 2

41 (28%)

17

24

3 ~ 5

39 (26%)

17

22

 > 5

25 (17%)

8

17

Stage, n (%)

0.154, ns

SS-S

44 (30%)

17 (39%)

27

SS-M

26 (18%)

9 (35%)

17

MS-RO⁻

57 (39%)

21 (37%)

36

MS-RO⁺

21 (14%)

13 (62%)

8

Organ involved³, n (%)

Bone

117 (79%)

46 (39%)

71

0.701, ns

Skin

61 (41%)

28 (46%)

33

0.346, ns

Lung

38 (26%)

13 (34%)

25

0.465, ns

Lymph node

21 (14%)

6 (29%)

15

0.368, ns

Liver

20 (14%)

8 (40%)

12

1.000, ns

Spleen

12 (8%)

6 (50%)

6

0.546, ns

Pituitary gland

11 (7%)

3 (27%)

8

0.527, ns

Bone marrow

6 (4%)

3 (50%)

3

0.683, ns

Thymus

5 (3%)

1 (20%)

4

0.648, ns

Sample type⁴, n (%)

Peripheral blood

78 (53%)

18 (23%)

60

0.000, ***

FFPE tissue

84 (57%)

45 (54%)

39

0.000, ***

Mutant TP53, n (%)

0.572, ns

 + 

72 (49%)

27 (38%)

45

−

76 (51%)

33 (43%)

43

Masses close to the lesion, n (%)

1.000, ns

 + 

71 (48%)

29 (41%)

42

−

77 (52%)

31 (40%)

46

Recurrence, n (%)(out of 136)

0.407, ns

 + 

41 (30%)

11

30

−

95 (70%)

45

50

Clinical outcome, n (%)(out of 136)

–

Improved

127 (93%)

49

78

Not

9 (7%)

6

3